Edition:
United Kingdom

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

13.27USD
8 Dec 2017
Change (% chg)

$0.38 (+2.91%)
Prev Close
$12.90
Open
$13.01
Day's High
$13.37
Day's Low
$13.01
Volume
409,593
Avg. Vol
749,951
52-wk High
$16.60
52-wk Low
$4.41

Chart for

About

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $2,478.36
Shares Outstanding(Mil.): 164.57
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Amicus Therapeutics Q3 loss per share $0.69

* Amicus therapeutics announces third quarter 2017 financial results and corporate updates

08 Nov 2017

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

BELGRADE Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

04 Oct 2017

UPDATE 1-Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

BELGRADE, Oct 4 Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

04 Oct 2017

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

BELGRADE, Oct 4 Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

04 Oct 2017

BRIEF-Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society

* Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society

04 Oct 2017

BRIEF-U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease

* U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease

19 Sep 2017

BRIEF-Amicus Therapeutics announces approval for Galafold™ for treatment of Fabry disease in Canada

* Amicus Therapeutics Inc announces approval for Galafold™ (Migalastat) for treatment of Fabry disease in Canada

14 Sep 2017

Amicus abandons wound treatment, focus shifts to future trial data

Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer's expanding pipeline.

13 Sep 2017

UPDATE 3-Amicus abandons wound treatment, focus shifts to future trial data

* Analysts express optimism about upcoming trial data (Updates share price, adds analyst comment)

13 Sep 2017

Amicus Therapeutics' wound treatment fails late-stage trial

Sept 13 U.S. drug developer Amicus Therapeutics Inc said on Wednesday its drug to treat wounds failed to meet the main goals of a late-stage clinical trial.

13 Sep 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €73.18 -0.03
Shire PLC (SHP.L) 3,648.00 +115.50
Shire PLC (3159084.L) -- --
Actelion Ltd (ATLN.S) -- --

Earnings vs. Estimates